Business
CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End
- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment in December 2023- Topline
About this update from Cns Pharmaceuticals, Inc.
[{"type":"text","content":"- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment in December 2023- Topline data from preplanned interim analysis from ongoing Berubicin potentially pivotal study expected in December 2023- Raised $2.6 million subsequent to quarter-endHOUSTON, TX / ACCESSWIRE / November 15, 2023 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) (\"CNS\" or the \"Company\"), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today reported its financial results for the quarter ended September 30, 2023 and reiterated upcoming milestones.\"Over the course of 2023, we have demonstrated solid execution and rapid progression of enrollment in our ongoing potentially pivotal study of Berubicin. We are preparing for the most significant milestones for patients, the Company and our stockholders in just a few short weeks, with interm data expected in December 2023,\" commented John Climaco, CEO of CNS Pharmaceuticals. \"With topline data from our interim analysis expected in the coming weeks, we are poised to determine whether or not the independent Data Safety Monitoring Board recommends continuing the study. We are hopeful that by the end of this study Berubicin will ultimately demonstrate life-saving value as a second-line treatment for patients with recurrent glioblastoma. We look forward to an exciting remainder of the year and building value for all stakeholders in the near and long-term.\"Recent Clinical AchievementsAchieved enrollment of 239 patients; The Company has opened 45 clinical trial sites of the 60 sites selected across the U.S., Italy, France, Spain, and Switzerland.Presented updated results from ongoing potentially pivotal study of Berubicin in adult patients with recurrent GBM after failure of standard first line therapy at the 2023 SNO/ASCO CNS Cancer Conference.Upcoming Expected MilestonesReport topline results of interim analysis expected in December 2023. Enrollment will continue during the interim analysis.Complete enrollment in December 2023.For more information about this trial, visit clinicaltrials.gov and reference identifier NCT04762069.The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions ...